The role of ubiquitination in TWEAK-stimulated signaling

Frontiers in Immunology

Volumn 4, Issue DEC, 2013, Pages

  Vucic, Domagoj ^a  

^a GENENTECH INC   (United States)

Author keywords

C IAP1; IAP; NF B; NIK; TRAF2; TRAF3; TWEAK; Ubiquitin

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RELATED WEAK INDUCER OF APOPTOSIS; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

GENE EXPRESSION; GENE MUTATION; MUSCLE ATROPHY; OVARY TUMOR; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 84892376734     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00472     Document Type: Review

References (70)

1. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem (1998) 67:425-79. doi:10.1146/annurev.biochem.67.1.425
2. Schulman BA, Harper JW. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat Rev Mol Cell Biol (2009) 10:319-31. doi:10.1038/nrm2673
3. Pickart CM, Fushman D. Polyubiquitin chains: polymeric protein signals. Curr Opin Chem Biol (2004) 8:610-6. doi:10.1016/j.cbpa.2004.09.009
4. Ikeda F, Dikic I. Atypical ubiquitin chains: new molecular signals. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep (2008) 9:536-42. doi:10.1038/embor.2008.93
5. Dynek JN, Goncharov T, Dueber EC, Fedorova AV, Izrael-Tomasevic A, Phu L, et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J (2010) 29:4198-209. doi:10.1038/emboj.2010.300
6. Emmerich CH, Schmukle AC, Walczak H. The emerging role of linear ubiquitination in cell signaling. Sci Signal (2011) 4:re5. doi:10.1126/scisignal.2002187
7. Vucic D, Dixit VM, Wertz IE. Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol (2011) 12:439-52. doi:10.1038/nrm3143
8. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem (2009) 78:399-434. doi:10.1146/annurev.biochem.78.101807.093809
9. Husnjak K, Dikic I. Ubiquitin-binding proteins: decoders of ubiquitin-mediated cellular functions. Annu Rev Biochem (2012) 81:291-322. doi:10.1146/annurev-biochem-051810-094654
10. Reyes-Turcu FE, Ventii KH, Wilkinson KD. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem (2009) 78:363-97. doi:10.1146/annurev.biochem.78.082307.091526
11. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci (2002) 27:19-26. doi:10.1016/S0968-0004(01)01995-8
12. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell (2001) 104:487-501. doi:10.1016/S0092-8674(01)00237-9
13. Wallach D, Arumugam TU, Boldin MP, Cantarella G, Ganesh KA, Goltsev Y, et al. How are the regulators regulated? The search for mechanisms that impose specificity on induction of cell death and NF-kappaB activation by members of the TNF/NGF receptor family. Arthritis Res (2002) 4(Suppl 3):S189-96. doi:10.1186/ar585
14. Li H, Lin X. Positive and negative signaling components involved in TNFalpha-induced NF-kappaB activation. Cytokine (2008) 41:1-8. doi:10.1016/j.cyto.2007.09.016
15. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer (2009) 9:537-49. doi:10.1038/nrc2694
16. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev (2004) 18:2195-224. doi:10.1101/gad.1228704
17. Scheidereit C. IκB kinase complexes: gateways to NF-κB activation and transcription. Oncogene (2006) 25:6685-705. doi:10.1038/sj.onc.1209934
18. Dejardin E. The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol (2006) 72:1161-79. doi:10.1016/j.bcp.2006.08.007
19. Burkly LC, Michaelson JS, Zheng TS. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev (2011) 244:99-114. doi:10.1111/j.1600-065X.2011.01054.x
20. Wajant H. The TWEAK-Fn14 system as a potential drug target. Br J Pharmacol (2013) 170:748-64. doi:10.1111/bph.12337
21. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S. TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem (2003) 278:36005-12. doi:10.1074/jbc.M304266200
22. Roos C, Wicovsky A, Muller N, Salzmann S, Rosenthal T, Kalthoff H, et al. Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J Immunol (2010) 185:1593-605. doi:10.4049/jimmunol.0903555
23. Fick A, Lang I, Schafer V, Seher A, Trebing J, Weisenberger D, et al. Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14). J Biol Chem (2012) 287:484-95. doi:10.1074/jbc.M111.287656
24. Han S, Yoon K, Lee K, Kim K, Jang H, Lee NK, et al. TNF-related weak inducer of apoptosis receptor, a TNF receptor superfamily member, activates NF-kappa B through TNF receptor-associated factors. Biochem Biophys Res Commun (2003) 305:789-96. doi:10.1016/S0006-291X(03)00852-0
25. Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, Schneider P, et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol (2008) 182:171-84. doi:10.1083/jcb.200801010
26. Li H, Mittal A, Paul PK, Kumar M, Srivastava DS, Tyagi SC, et al. Tumor necrosis factor-related weak inducer of apoptosis augments matrix metalloproteinase 9 (MMP-9) production in skeletal muscle through the activation of nuclear factor-kappaB-inducing kinase and p38 mitogen-activated protein kinase: a potential role of MMP-9 in myopathy. J Biol Chem (2009) 284:4439-50. doi:10.1074/jbc.M805546200
27. Mace PD, Smits C, Vaux DL, Silke J, Day CL. Asymmetric recruitment of cIAPs by TRAF2. J Mol Biol (2010) 400:8-15. doi:10.1016/j.jmb.2010.04.055
28. Zheng C, Kabaleeswaran V, Wang Y, Cheng G, Wu H. Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation. Mol Cell (2010) 38:101-13. doi:10.1016/j.molcel.2010.03.009
29. Varfolomeev E, Goncharov T, Maecker H, Zobel K, Komuves LG, Deshayes K, et al. Cellular inhibitors of apoptosis are global regulators of NF-kappaB and MAPK activation by members of the TNF family of receptors. Sci Signal (2012) 5:ra22. doi:10.1126/scisignal.2001878
30. Tokunaga F, Iwai K. Linear ubiquitination: a novel NF-kappaB regulatory mechanism for inflammatory and immune responses by the LUBAC ubiquitin ligase complex. Endocr J (2012) 8:641-52. doi:10.1507/endocrj.EJ12-0148
31. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell (2007) 131:669-81. doi:10.1016/j.cell.2007.10.030
32. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell (2007) 131:682-93. doi:10.1016/j.cell.2007.10.037
33. Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng PH, Keats JJ, Wang H, et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol (2008) 9:1364-70. doi:10.1038/ni.1678
34. Varfolomeev E, Vucic D. (Un)expected roles of c-IAPs in apoptotic and NF-κB signaling pathways. Cell Cycle (2008) 7:1511-21. doi:10.4161/cc.7.11.5959
35. Feltham R, Moulin M, Vince JE, Mace PD, Wong WW, Anderton H, et al. Tumor necrosis factor (TNF) signaling, but not TWEAK (TNF-like weak inducer of apoptosis)-triggered cIAP1 (cellular inhibitor of apoptosis protein 1) degradation, requires cIAP1 RING dimerization and E2 binding. J Biol Chem (2010) 285:17525-36. doi:10.1074/jbc.M109.087635
36. Wicovsky A, Salzmann S, Roos C, Ehrenschwender M, Rosenthal T, Siegmund D, et al. TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling. Cell Death Differ (2009) 16:1445-59. doi:10.1038/cdd.2009.80
37. Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol (2002) 3:958-65. doi:10.1038/ni842
38. Kayagaki N, Yan M, Seshasayee D, Wang H, Lee W, French DM, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity (2002) 17:515-24. doi:10.1016/S1074-7613(02)00425-9
39. Xu LG, Shu HB. TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-kappa B activation and IL-10 production. J Immunol (2002) 169:6883-9.
40. Ni CZ, Oganesyan G, Welsh K, Zhu X, Reed JC, Satterthwait AC, et al. Key molecular contacts promote recognition of the BAFF receptor by TNF receptor-associated factor 3: implications for intracellular signaling regulation. J Immunol (2004) 173:7394-400.
41. Goncharov T, Niessen K, De Almagro MC, Izrael-Tomasevic A, Fedorova AV, Varfolomeev E, et al. OTUB1 modulates c-IAP1 stability to regulate signalling pathways. EMBO J (2013) 32:1103-14. doi:10.1038/emboj.2013.62
42. Haas TL, Emmerich CH, Gerlach B, Schmukle AC, Cordier SM, Rieser E, et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell (2009) 36:831-44. doi:10.1016/j.molcel.2009.10.013
43. Paul PK, Bhatnagar S, Mishra V, Srivastava S, Darnay BG, Choi Y, et al. The E3 ubiquitin ligase TRAF6 intercedes in starvation-induced skeletal muscle atrophy through multiple mechanisms. Mol Cell Biol (2012) 32:1248-59. doi:10.1128/MCB.06351-11
44. Xia ZP, Chen ZJ. TRAF2: a double-edged sword? Sci STKE (2005) 2005:e7.
45. Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature (2010) 465:1084-8. doi:10.1038/nature09128
46. Vince JE, Pantaki D, Feltham R, Mace PD, Cordier SM, Schmukle AC, et al. TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf-{kappa}b and to prevent tnf-induced apoptosis. J Biol Chem (2009) 284:35906-15. doi:10.1074/jbc.M109.072256
47. Yin Q, Lamothe B, Darnay BG, Wu H. Structural basis for the lack of E2 interaction in the RING domain of TRAF2. Biochemistry (2009) 48:10558-67. doi:10.1021/bi901462e
48. Adada MM, Orr-Gandy KA, Snider AJ, Canals D, Hannun YA, Obeid LM, et al. Sphingosine kinase 1 regulates tumor necrosis factor-mediated RANTES induction through p38 mitogen-activated protein kinase but independently of nuclear factor kappaB activation. J Biol Chem (2013) 288:27667-79. doi:10.1074/jbc.M113.489443
49. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 12:115-30. doi:10.1016/j.ccr.2007.07.004
50. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 12:131-44. doi:10.1016/j.ccr.2007.07.003
51. Gardam S, Turner VM, Anderton H, Limaye S, Basten A, Koentgen F, et al. Deletion of cIAP1 and cIAP2 in murine B lymphocytes constitutively activates cell survival pathways and inactivates the germinal center response. Blood (2011) 117:4041-51. doi:10.1182/blood-2010-10-312793
52. Enwere EK, Holbrook J, Lejmi-Mrad R, Vineham J, Timusk K, Sivaraj B, et al. TWEAK and cIAP1 regulate myoblast fusion through the noncanonical NF-kappaB signaling pathway. Sci Signal (2012) 5:ra75. doi:10.1126/scisignal.2003086
53. Dueber EC, Schoeffler AJ, Lingel A, Elliott JM, Fedorova AV, Giannetti AM, et al. Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination. Science (2011) 334:376-80. doi:10.1126/science.1207862
54. Feltham R, Bettjeman B, Budhidarmo R, Mace PD, Shirley S, Condon SM, et al. Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization. J Biol Chem (2011) 286:17015-28. doi:10.1074/jbc.M111.222919
55. Dougan M, Dougan S, Slisz J, Firestone B, Vanneman M, Draganov D, et al. IAP inhibitors enhance co-stimulation to promote tumor immunity. J Exp Med (2010) 207:2195-206. doi:10.1084/jem.20101123
56. Knights AJ, Fucikova J, Pasam A, Koernig S, Cebon J. Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy. Cancer Immunol Immunother (2012) 62:321-35. doi:10.1007/s00262-012-1342-1
57. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov (2012) 11:109-24. doi:10.1038/nrd3627
58. Salzmann S, Lang I, Rosenthal A, Schafer V, Weisenberger D, Carmona Arana JA, et al. TWEAK inhibits TRAF2-mediated CD40 signaling by destabilization of CD40 signaling complexes. J Immunol (2013) 191:2308-18. doi:10.4049/jimmunol.1202899
59. Fong A, Sun SC. Genetic evidence for the essential role of beta-transducin repeat-containing protein in the inducible processing of NF-kappa B2/p100. J Biol Chem (2002) 277:22111-4. doi:10.1074/jbc.C200151200
60. Xiao G, Fong A, Sun SC. Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation. J Biol Chem (2004) 279:30099-105. doi:10.1074/jbc.M401428200
61. Sun SC, Ley SC. New insights into NF-kappaB regulation and function. Trends Immunol (2008) 29:469-78. doi:10.1016/j.it.2008.07.003
62. Arabi A, Ullah K, Branca RM, Johansson J, Bandarra D, Haneklaus M, et al. Proteomic screen reveals Fbw7 as a modulator of the NF-kappaB pathway. Nat Commun (2012) 3:976. doi:10.1038/ncomms1975
63. Busino L, Millman SE, Pagano M. SCF-mediated degradation of p100 (NF-kappaB2): mechanisms and relevance in multiple myeloma. Sci Signal (2012) 5(253):pt14. doi:10.1126/scisignal.2003408
64. Busino L, Millman SE, Scotto L, Kyratsous CA, Basrur V, O'Connor O, et al. Fbxw7alpha-and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol (2012) 14:375-85. doi:10.1038/ncb2463
65. Fukushima H, Matsumoto A, Inuzuka H, Zhai B, Lau AW, Wan L, et al. SCF(Fbw7) modulates the NFkB signaling pathway by targeting NFkB2 for ubiquitination and destruction. Cell Rep (2012) 1:434-43. doi:10.1016/j.celrep.2012.04.002
66. Edelmann MJ, Iphofer A, Akutsu M, Altun M, Di Gleria K, Kramer HB, et al. Structural basis and specificity of human otubain 1-mediated deubiquitination. Biochem J (2009) 418:379-90. doi:10.1042/BJ20081318
67. Yamaguchi N, Oyama M, Kozuka-Hata H, Inoue J. Involvement of A20 in the molecular switch that activates the non-canonical NF-small kappa B pathway. Sci Rep (2013) 3:2568. doi:10.1038/srep02568
68. Evans PC, Smith TS, Lai MJ, Williams MG, Burke DF, Heyninck K, et al. A novel type of deubiquitinating enzyme. J Biol Chem (2003) 278:23180-6. doi:10.1074/jbc.M301863200
69. Hu H, Brittain GC, Chang JH, Puebla-Osorio N, Jin J, Zal A, et al. OTUD7B controls non-canonical NF-kappaB activation through deubiquitination of TRAF3. Nature (2013) 494:371-4. doi:10.1038/nature11831
70. de Leon-Boenig G, Bowman KK, Feng JA, Crawford T, Everett C, Franke Y, et al. The crystal structure of the catalytic domain of the NF-kappaB inducing kinase reveals a narrow but flexible active site. Structure (2012) 20:1704-14. doi:10.1016/j.str.2012.07.013